Sign in
Not yet recruitingNo phase

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis

Key facts

Who runs it
Santersus AG
Where
Germany, Switzerland, and United Kingdom9 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
73 people, planned
Started
1 Jul 2025
Expected to end
28 May 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • NucleoCapture device
Record updated
29 November 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Adult patients aged 18-75
  • Proven or suspected respiratory sepsis aetiology
  • Acute respiratory failure currently requiring invasive mechanical ventilation for not more than 48 hours duration
  • Horowitz Index for Lung Function (Pa02/Fi02 Ratio) ≤200mmHg or ≤26.6kPa
  • Sequential organ failure assessment score (SOFA) ≥4 and ≤ 14
  • Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law)

Who cannot take part

  • The use of other non-routine extracorporeal sepsis treatments such as very high flux renal replacement therapy (>60ml/kg/h total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc)
  • Long term oxygen therapy or home oxygen use
  • Solid organ transplant and concomitant use of immunosuppression
  • Prior use of cardiopulmonary resuscitation (CPR) in index admission
  • Active bleeding
  • Heparin allergy if heparin is required for therapeutic apheresis
  • Metastatic disease with life expectancy of <12 months and ECOG score of at least 2
  • Haematological malignancy if not in remission
  • Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D)
  • Known allergy to components of NucleoCapture
  • Presence of severe multiple organ failure at the point of enrolment as evidenced by:; Severe refractory vasoplegic failure; Norepinephrine dose > 0.60 μg/kg/min; Use of epinephrine; Concomitant cardiogenic shock, clinically suspected or CI<2.2 if measured; Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan; Coagulopathy as defined by platelet count <50
  • Expected duration of invasive mechanical ventilation less than 48 hours
  • Calculated Plasma Volume greater than 5000ml as determined by an estimation of total blood volume (according to Nadler's formula, incorporating height, weight and sex) multiplied by (1- Haematocrit). A total blood volume calculator is available at https://www.omnicalculator.com/health/blood-volume
  • Liver cirrhosis (histologically proven or clinically suspected)
  • Citrate intolerance if citrate is required for therapeutic apheresis
  • Requirement for extracorporeal membrane oxygenation (ECMO)
  • Patient expected to die within 48 hours of admission to ICU
  • Current Participation in another interventional clinical trial
  • Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in sepsis patients.

The 2 groups in the trial

  • NucleoCapture TreatmentTreatment being tested

    Participants in the NucleoCapture treatment arm will receive Standard of Care plus three treatment sessions with the NucleoCapture treatment device. The device consists of 100ml NucleoCapture selective adsorber.

    Treatment: NucleoCapture device

  • Standard of CareNo study treatment, for comparison

    Participants in the Standard of Care arm will receive standard medical care alone.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
Criteria questions
Built from NCT05647096, who can take part
Record updated
29 November 2024